For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total Omnipod of 17% to 21%; U.S. Omnipod of 16% to 20%; International Omnipod of 22% to 26%; Drug Delivery of (55)% to (45)%. For the year ending December 31, 2025, the Company expects gross margin of approximately 70.5% and operating margin of approximately 16.5%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- PODD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biote announcesTerry Weber retires Bret Christensen named CEO
- 3 Best Growth Stocks to Buy Now, 1/31/2025, According to Analysts
- Insulet launches Omnipod 5 in five more countries in Europe
- Insulet price target raised to $315 from $305 at Bernstein